Results 121 to 130 of about 17,876 (257)
Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.This review presents a framework for selecting Claudin 18.2 (CLDN18.2)‐directed treatment modalities in pancreatic ductal adenocarcinoma according to tumour antigen coverage and spatial distribution. Representative assessment at baseline and reassessment after progression can guide treatment adaptation over time.
Ruyu Tan +5 more
wiley +1 more source
Frontiers in OncologyBackgroundThe effectiveness of a dexamethasone-sparing strategy in the treatment of breast cancer with anthracycline-cyclophosphamide therapy when combined with first-generation 5-HT3 receptor antagonists (RAs) and neurokinin-1 RAs is unclear.
Daichi Watanabe +15 more
doaj +1 more source
Research in Nursing &Health, Volume 49, Issue 5, Page 595-611, October 2026.ABSTRACT Colorectal cancer (CRC) is a leading cause of cancer mortality in the United States. Many patients with CRC experience physical and psychological symptoms that diminish quality of life and are shaped by social determinants of health (SDOH) and diet quality.
Youran Lee +18 more
wiley +1 more source
Therapeutics and Clinical Risk Management, 2017 Afsaneh Vazin, Davood Eslami, Ebrahim Sahebi Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran Abstract: Nausea and vomiting (NV) are the most prevalent adverse effects of chemotherapy (CT).
Vazin A, Eslami D, Sahebi E
doaj
, 2011 Aims: XELOX (combination therapy of capecitabine and oxaliplatin) is gaining much popularity in the treatment of gastrointestinal cancers at the National Cancer Centre Singapore. This study is designed to elucidate the incidences of nausea and vomiting
Chan, Alexandre +3 more
core
Pediatric Anesthesia, Volume 36, Issue 10, Page 1196-1206, October 2026.ABSTRACT Introduction Pediatric ambulatory surgery has become the dominant model of surgical care in the United States, driven primarily by economic forces. There is variability in regional practice patterns, quality improvement cycles, and outcomes. Opportunity exists to overcome knowledge gaps and provide sustainable pathways of quality improvement ...
Jennifer L. Chiem +6 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 10, October 2026.Real‐world prescription data from 6230 adolescents and adults living with sickle cell disease (SCD) were combined with a drug–drug interaction (DDI) database to characterize the population‐level DDI risk. The findings support a DDI risk assessment for development of novel SCD therapies and during clinical management of SCD.ABSTRACTSickle cell disease ...
Rune Aabjerg Nørgaard +4 more
wiley +1 more source
Cooling down for going up: Could selective ‘brain chilling’ mitigate high‐altitude illness?
Experimental Physiology, EarlyView.
Adnan Haq, Damian M. Bailey
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8757-8768, October 2026.ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris +5 more
wiley +1 more source
Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.ABSTRACT Pediatric radiation therapy presents unique challenges compared to adult treatments, including those of immobilization, potential need for sedation, and the critical importance of accurate, reproducible positioning. Additionally, heightened attention to imaging doses is necessary to minimize long‐term toxicity in survivors.
Parham Alaei +17 more
wiley +1 more source